Razzaghi Mohammadreza, Sheibani Fatemeh, Kimia Negin, Razzaghi Zahra, Chenari Zeynab, Ashrafi Farzad, Barati Maryam, Advani Soroor
Laser application in medical Sciences research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Functional neurosurgery research center, Shahid beheshti university of medical sciences, Tehran, Iran.
Photodiagnosis Photodyn Ther. 2024 Apr;46:103991. doi: 10.1016/j.pdpdt.2024.103991. Epub 2024 Feb 16.
Alzheimer's Disease (AD), undergoing a faster increase in occurrence than any other type of dementia, lacks a curative remedy despite advanced discoveries. To explore the realm of non-pharmacologic therapies, our study evaluates the 12-week impact of non-invasive Photobiomodulation (PBM) on cognitive and psychological aspects in individuals with AD and minimal cognitive impairment (MCI). The urgency of exploring innovative interventions is underscored by the rising occurrence of AD, particularly in regions with aging populations like Iran.
13 patients (6 case patients and 7 control patients) participated in the study. Sham treatment was administered to seven individuals, while another six received PBM treatment over 12 weeks, with daily at-home LED (810 nm wavelength) device usage lasting 20 min. Initially, the patient and their caregiver participated in two hospital sessions to acquaint them with the device's operation.
The mean reduction of Hamilton's anxiety questionnaire score was 3.33±6.08 in the intervention group and 2.00±3.46 in the control group (p-value=0.836). The mean score reduction of the Hamilton depression questionnaire was 3.16±3.86 in the intervention group and 4.85±6.20 in the control group (p-value=0.836). The mean score of the DAD questionnaire in the intervention group before the study was 25.50±13.13 and after the intervention was 29.83±12.12 (p-value=0.084) and in the control group it was 29.71±8.19 and after the study was 29±0.972 (p-value = 0.526). The mean changes in the DAD questionnaire score in the intervention group increased by 4.33±4.92 and decreased by 0.71±2.81 in the control group (p-value=0.041).
In general, PBM appears to hold promise as a potentially safe method for enhancing the cognitive, functional, and psychological status of individuals with Alzheimer's disease, though further research with larger sample size and cautious interpretation are warranted.
阿尔茨海默病（AD）的发病率增长速度比其他任何类型的痴呆症都要快，尽管有先进的研究发现，但仍缺乏治愈方法。为了探索非药物治疗领域，我们的研究评估了非侵入性光生物调节（PBM）对AD和轻度认知障碍（MCI）患者认知和心理方面的12周影响。AD发病率的上升，尤其是在伊朗等人口老龄化地区，凸显了探索创新干预措施的紧迫性。
13名患者（6例患者和7例对照患者）参与了该研究。对7名个体进行了假治疗，另外6名在12周内接受了PBM治疗，每天在家使用LED（810纳米波长）设备，持续20分钟。最初，患者及其护理人员参加了两次医院培训，让他们熟悉设备的操作。
干预组汉密尔顿焦虑问卷评分的平均降低值为3.33±6.08，对照组为2.00±3.46（p值=0.836）。干预组汉密尔顿抑郁问卷评分的平均降低值为3.16±3.86，对照组为4.85±6.20（p值=0.836）。干预组在研究前DAD问卷的平均评分为25.50±13.13，干预后为29.83±12.12（p值=0.084），对照组在研究前为29.71±8.19，研究后为29±0.972（p值=0.526）。干预组DAD问卷评分的平均变化增加了4.33±4.92，对照组减少了0.71±2.81（p值=0.041）。
总体而言，PBM似乎有望成为一种潜在安全的方法，用于改善阿尔茨海默病患者的认知、功能和心理状态，不过需要进行更大样本量的进一步研究并谨慎解读。
